Nasus Pharma Ltd is a clinical-stage pharmaceutical company developing intranasal powder formulations for acute medical emergencies. The company's pipeline focuses on Powder-Based Intranasal (PBI) products designed for rapid administration in time-sensitive situations. Its lead candidates include NS002, an intranasal epinephrine spray for severe allergic reactions, and NS001, an intranasal naloxone powder formulation for opioid overdose reversal. Both products target existing markets where alternative delivery methods are established, though the company's formulations target faster onset or improved usability compared to conventional approaches.
The company was incorporated in 2019 and is headquartered in Tel Aviv-Yafo, Israel, operating as a publicly listed entity on the NYSE. As a pre-revenue clinical-stage entity, Nasus Pharma has not yet commercialized products and generates no meaningful revenue streams. The company's current operations reflect typical early-stage development activities, including clinical trials, regulatory submissions, and product development. With a single full-time employee listed on its roster, the organization operates at minimal operational scale, relying on contracted research organizations and external partnerships to execute its development programs.
No 10-K filings found.